Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2011

Open Access 01-12-2011 | Research

LIM kinase1 modulates function of membrane type matrix metalloproteinase 1: implication in invasion of prostate cancer cells

Authors: Tenekua Tapia, Richard Ottman, Ratna Chakrabarti

Published in: Molecular Cancer | Issue 1/2011

Login to get access

Abstract

Background

LIM kinase 1 (LIMK1) is an actin and microtubule cytoskeleton modulatory protein that is overexpressed in a number of cancerous tissues and cells and also promotes invasion and metastasis of prostate and breast cancer cells. Membrane type matrix metalloproteinase 1 (MT1-MMP) is a critical modulator of extracellular matrix (ECM) turnover through pericellular proteolysis and thus plays crucial roles in neoplastic cell invasion and metastasis. MT1-MMP and its substrates pro-MMP-2 and pro-MMP-9 are often overexpressed in a variety of cancers including prostate cancer and the expression levels correlate with the grade of malignancy in prostate cancer cells. The purpose of this study is to determine any functional relation between LIMK1 and MT1-MMP and its implication in cell invasion.

Results

Our results showed that treatment with the hydroxamate inhibitor of MT1-MMP, MMP-2 and MMP-9 ilomastat inhibited LIMK1-induced invasion of benign prostate epithelial cells. Over expression of LIMK1 resulted in increased collagenolytic activity of MMP-2, and secretion of pro-MMP2 and pro-MMP-9. Cells over expressing LIMK1 also exhibited increased expression of MT1-MMP, transcriptional activation and its localization to the plasma membrane. LIMK1 physically associates with MT1-MMP and is colocalized with it to the Golgi vesicles. We also noted increased expression of both MT1-MMP and LIMK1 in prostate tumor tissues.

Conclusion

Our results provide new information on regulation of MT1-MMP function by LIMK1 and showed for the first time, involvement of MMPs in LIMK1 induced cell invasion.
Appendix
Available only for authorised users
Literature
1.
Okano I, Hiraoka J, Otera H, Nunoue K, Ohashi K, Iwashita S, Hirai M, Mizuno K: Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal LIM motifs. J Biol Chem. 1995, 270: 31321-31330. 10.1074/jbc.270.52.31321CrossRefPubMed
2.
Davila M, Frost AR, Grizzle WE, Chakrabarti R: LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem. 2003, 278: 36868-36875. 10.1074/jbc.M306196200CrossRefPubMed
3.
Yoshioka K, Foletta V, Bernard O, Itoh K: A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA. 2003, 100: 7247-7252. 10.1073/pnas.1232344100PubMedCentralCrossRefPubMed
4.
Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R: LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer. 2006, 118: 2703-2710. 10.1002/ijc.21650CrossRefPubMed
5.
Davila M, Jhala D, Ghosh D, Grizzle WE, Chakrabarti R: Expression of LIM kinase 1 is associated with reversible G1/S phase arrest, chromosomal instability and prostate cancer. Mol Cancer. 2007, 6: 40- 10.1186/1476-4598-6-40PubMedCentralCrossRefPubMed
6.
Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P: Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature. 1998, 393: 805-809. 10.1038/31729CrossRefPubMed
7.
Edwards DC, Gill GN: Structural features of LIM kinase that control effects on the actin cytoskeleton. J Biol Chem. 1999, 274: 11352-11361. 10.1074/jbc.274.16.11352CrossRefPubMed
8.
Edwards DC, Sanders LC, Bokoch GM, Gill GN: Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999, 1: 253-259. 10.1038/12963CrossRefPubMed
9.
Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K, Nishida E, Mizuno K: Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature. 1998, 393: 809-812. 10.1038/31735CrossRefPubMed
10.
Itoh Y, Seiki M: MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol. 2006, 206: 1-8. 10.1002/jcp.20431CrossRefPubMed
11.
Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25: 9-34. 10.1007/s10555-006-7886-9CrossRefPubMed
12.
Li XY, Ota I, Yana I, Sabeh F, Weiss SJ: Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase. Mol Biol Cell. 2008, 19: 3221-3233. 10.1091/mbc.E08-01-0016PubMedCentralCrossRefPubMed
13.
Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, Saiki I: Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett. 2000, 155: 173-179. 10.1016/S0304-3835(00)00425-0CrossRefPubMed
14.
15.
Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995, 270: 5331-5338. 10.1074/jbc.270.10.5331CrossRefPubMed
16.
Wang Z, Juttermann R, Soloway PD: TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem. 2000, 275: 26411-26415. 10.1074/jbc.M001270200PubMedCentralCrossRefPubMed
17.
Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, Aoki T, Seiki M: Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 2001, 20: 4782-4793. 10.1093/emboj/20.17.4782PubMedCentralCrossRefPubMed
18.
Lehti K, Lohi J, Juntunen MM, Pei D, Keski-Oja J: Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. J Biol Chem. 2002, 277: 8440-8448. 10.1074/jbc.M109128200CrossRefPubMed
19.
Golubkov VS, Chekanov AV, Shiryaev SA, Aleshin AE, Ratnikov BI, Gawlik K, Radichev I, Motamedchaboki K, Smith JW, Strongin AY: Proteolysis of the membrane type-1 matrix metalloproteinase prodomain: implications for a two-step proteolytic processing and activation. J Biol Chem. 2007, 282: 36283-36291. 10.1074/jbc.M706290200CrossRefPubMed
20.
Nie J, Pei J, Blumenthal M, Pei D: Complete restoration of cell surface activity of transmembrane-truncated MT1-MMP by a glycosylphosphatidylinositol anchor. Implications for MT1-MMP-mediated prommp2 activation and collagenolysis in three-dimensions. J Biol Chem. 2007, 282: 6438-6443. 10.1074/jbc.M607337200CrossRefPubMed
21.
Remacle AG, Chekanov AV, Golubkov VS, Savinov AY, Rozanov DV, Strongin AY: O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP). J Biol Chem. 2006, 281: 16897-16905. 10.1074/jbc.M600295200CrossRefPubMed
22.
Lafleur MA, Mercuri FA, Ruangpanit N, Seiki M, Sato H, Thompson EW: Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain. J Biol Chem. 2006, 281: 6826-6840. 10.1074/jbc.M513084200CrossRefPubMed
23.
Toth M, Chvyrkova I, Bernardo MM, Hernandez-Barrantes S, Fridman R: Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun. 2003, 308: 386-395. 10.1016/S0006-291X(03)01405-0CrossRefPubMed
24.
Hoshino D, Tomari T, Nagano M, Koshikawa N, Seiki M: A novel protein associated with membrane-type 1 matrix metalloproteinase binds p27(kip1) and regulates RhoA activation, actin remodeling, and matrigel invasion. J Biol Chem. 2009, 284: 27315-27326. 10.1074/jbc.M109.041400PubMedCentralCrossRefPubMed
25.
Wilson SR, Gallagher S, Warpeha K, Hawthorne SJ: Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate. 2004, 60: 168-174. 10.1002/pros.20047CrossRefPubMed
26.
del Peso L, Hernandez-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C, Lacal JC: Rho proteins induce metastatic properties in vivo. Oncogene. 1997, 15: 3047-3057. 10.1038/sj.onc.1201499CrossRefPubMed
27.
Malliri A, Symons M, Hennigan RF, Hurlstone AF, Lamb RF, Wheeler T, Ozanne BW: The transcription factor AP-1 is required for EGF-induced activation of rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion of A431 cells. J Cell Biol. 1998, 143: 1087-1099. 10.1083/jcb.143.4.1087PubMedCentralCrossRefPubMed
28.
Zhuge Y, Xu J: Rac1 mediates type I collagen-dependent MMP-2 activation. role in cell invasion across collagen barrier. J Biol Chem. 2001, 276: 16248-16256.CrossRefPubMed
29.
Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim. 1995, 31: 14-24. 10.1007/BF02631333CrossRefPubMed
30.
Munshi HG, Wu YI, Mukhopadhyay S, Ottaviano AJ, Sassano A, Koblinski JE, Platanias LC, Stack MS: Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem. 2004, 279: 39042-39050. 10.1074/jbc.M404958200CrossRefPubMed
31.
Munshi HG, Wu YI, Ariztia EV, Stack MS: Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J Biol Chem. 2002, 277: 41480-41488. 10.1074/jbc.M207695200CrossRefPubMed
32.
Mallik I, Davila M, Tapia T, Schanen B, Chakrabarti R: Androgen regulates Cdc6 transcription through interactions between androgen receptor and E2F transcription factor in prostate cancer cells. Biochim Biophys Acta. 2008, 1783: 1737-1744. 10.1016/j.bbamcr.2008.05.006CrossRefPubMed
33.
Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J: Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis. 2004, 7: 327-332. 10.1038/sj.pcan.4500750CrossRefPubMed
34.
Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella RL, Fridman R, Cher ML: Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase. A Pivotal Role in Bone Response and Intraosseous Tumor Growth. Am J Pathol. 2007
35.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000, 18: 1135-1149.PubMed
36.
Boghaert ER, Chan SK, Zimmer C, Grobelny D, Galardy RE, Vanaman TC, Zimmer SG: Inhibition of collagenolytic activity relates to quantitative reduction of invasion in vitro in a c-Ha-ras transfected glial cell line. J Neurooncol. 1994, 21: 141-150. 10.1007/BF01052898CrossRefPubMed
37.
Golubkov VS, Boyd S, Savinov AY, Chekanov AV, Osterman AL, Remacle A, Rozanov DV, Doxsey SJ, Strongin AY: Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J Biol Chem. 2005, 280: 25079-25086. 10.1074/jbc.M502779200CrossRefPubMed
38.
Cao J, Chiarelli C, Kozarekar P, Adler HL: Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis. Thromb Haemost. 2005, 93: 770-778.PubMed
39.
Daja MM, Niu X, Zhao Z, Brown JM, Russell PJ: Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2003, 6: 15-26. 10.1038/sj.pcan.4500609CrossRefPubMed
40.
Sroka IC, Nagle RB, Bowden GT: Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia. 2007, 9: 406-417. 10.1593/neo.07193PubMedCentralCrossRefPubMed
41.
Gamell C, Osses N, Bartrons R, Ruckle T, Camps M, Rosa JL, Ventura F: BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity. J Cell Sci. 2008, 121: 3960-3970. 10.1242/jcs.031286CrossRefPubMed
42.
Vlecken DH, Bagowski CP: LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer cells. Zebrafish. 2009, 6: 433-439. 10.1089/zeb.2009.0602CrossRefPubMed
43.
Rosel D, Brabek J, Tolde O, Mierke CT, Zitterbart DP, Raupach C, Bicanova K, Kollmannsberger P, Pankova D, Vesely P, Folk P, Fabry B: Up-regulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces. Mol Cancer Res. 2008, 6: 1410-1420. 10.1158/1541-7786.MCR-07-2174CrossRefPubMed
44.
Mishima T, Naotsuka M, Horita Y, Sato M, Ohashi K, Mizuno K: LIM-kinase is critical for the mesenchymal-to-amoeboid cell morphological transition in 3D matrices. Biochem Biophys Res Commun. 392: 577-581.
45.
Lin T, Zeng L, Liu Y, DeFea K, Schwartz MA, Chien S, Shyy JY: Rho-ROCK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element binding proteins. Circ Res. 2003, 92: 1296-1304. 10.1161/01.RES.0000078780.65824.8BCrossRefPubMed
46.
Rosso S, Bollati F, Bisbal M, Peretti D, Sumi T, Nakamura T, Quiroga S, Ferreira A, Caceres A: LIMK1 regulates Golgi dynamics, traffic of Golgi-derived vesicles, and process extension in primary cultured neurons. Mol Biol Cell. 2004, 15: 3433-3449. 10.1091/mbc.E03-05-0328PubMedCentralCrossRefPubMed
47.
Nishimura Y, Yoshioka K, Bernard O, Bereczky B, Itoh K: A role of LIM kinase 1/cofilin pathway in regulating endocytic trafficking of EGF receptor in human breast cancer cells. Histochem Cell Biol. 2006, 126: 627-638. 10.1007/s00418-006-0198-xCrossRefPubMed
Metadata
Title
LIM kinase1 modulates function of membrane type matrix metalloproteinase 1: implication in invasion of prostate cancer cells
Authors
Tenekua Tapia
Richard Ottman
Ratna Chakrabarti
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2011
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-10-6

Other articles of this Issue 1/2011

Molecular Cancer 1/2011 Go to the issue

Research

Lipid phosphate phosphatase-3 regulates tumor growth via β-catenin and Cyclin-D1 signaling

Research

Sodium ion channel mutations in glioblastoma patients correlate with shorter survival

Research

PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro

Research

Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma

Research

A MCP1 fusokine with CCR2-specific tumoricidal activity

Research

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits